Skip to main content

Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial

In brief

Peanut immunotherapy did not improve quality of life over standard care

In a trial of 65 children aged 10 to 16, peanut oral immunotherapy did not improve quality-of-life scores more than standard care over 13.5 months. Reaching the trial's peanut-tolerance target also was not linked to better scores, while treatment-related serious adverse events were associated with less favorable caregiver ratings. Longer-term effects remain unclear.

Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (Q1)
Published
20 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Alice L Flanagan, Isabelle M L Bosi, Elizabeth H Barnes, Peter Hsu, Dianne E Campbell
PMID
43065152
DOI
10.1111/cea.70476

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 22 November 2026): Randomized peanut immunotherapy trial evaluates quality-of-life outcomes

Abstract

BACKGROUND: Health-related quality of life (HRQoL) findings have varied between peanut oral immunotherapy (OIT) trials. The objective of this study was to compare changes in the HRQoL between the OIT and standard (control) treatment groups during the OPIA peanut OIT double-blind randomised controlled trial and at long-term follow-up. METHODS: OPIA was a single-centre, 3-arm, double-blind placebo-controlled trial of peanut OIT in children aged 10-16 years. Standardised questionnaires (FAQLQ, FAIM, FAQLQ-Parent Burden, PSS) and bespoke surveys were administered at 0, 6, 12 and 13.5 months, with 3-year follow-up. Changes in scores at different time points were analysed descriptively and using 2-tailed T tests. A GEE model investigated the interaction between change in HRQoL score, treatment (OIT vs. standard care) and time. 3 year follow-up surveys were analysed using descriptive statistics and qualitative analysis. RESULTS: Sixty-five subjects were randomised and 61 participants completed the study. There was no evidence of difference in HRQoL score changes between the OIT and standard treatment groups from baseline to 12 months or 13.5 months. Furthermore, achieving OPIA's primary efficacy endpoint (tolerance of ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at month 13.5 double blind placebo-controlled food challenge was not associated with a more favourable change in FAQLQ from baseline to end of study. Changes in global FAQLQ-Parent proxy (FAQLQ-PF) scores from baseline to 12 months were less favourable for carers of children who had experienced treatment-related serious adverse events compared to those without such events (mean change 0.10 vs. -0.97, 0.0063). CONCLUSIONS: OIT did not confer a HRQoL benefit over standard care in this cohort, based upon the tools used to assess HRQoL. Treatment-related serious adverse effects negatively impacted FAQLQ-Parent proxy scores.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.